Assembly, Activation, and Substrate Specificity of Cyclin D1/Cdk2 Complexes

Overview

Journal Biochemistry

Specialty Biochemistry

Date 2013 May 1

PMID 23627734

Citations 13

Authors

Stephan C Jahn

Mary E Law

Patrick E Corsino

Thomas C Rowe

Bradley J Davis

Brian K Law

Affiliations

Soon will be listed here.

Abstract

Previous studies have shown conflicting data regarding cyclin D1/cyclin-dependent kinase 2 (Cdk2) complexes, and considering the widespread overexpression of cyclin D1 in cancer, it is important to fully understand their relevance. While many have shown that cyclin D1 and Cdk2 form active complexes, others have failed to show activity or association. Here, using a novel p21-PCNA fusion protein as well as p21 mutant proteins, we show that p21 is a required scaffolding protein, with cyclin D1 and Cdk2 failing to complex in its absence. These p21/cyclin D1/Cdk2 complexes are active and also bind the trimeric PCNA complex, with each trimer capable of independently binding distinct cyclin/Cdk complexes. We also show that increased p21 levels due to treatment with chemotherapeutic agents result in increased formation and kinase activity of cyclin D1/Cdk2 complexes, and that cyclin D1/Cdk2 complexes are able to phosphorylate a number of substrates in addition to Rb. Nucleophosmin and Cdh1, two proteins important for centrosome replication and implicated in the chromosomal instability of cancer, are shown to be phosphorylated by cyclin D1/Cdk2 complexes. Additionally, polypyrimidine tract binding protein-associated splicing factor (PSF) is identified as a novel Cdk2 substrate, being phosphorylated by Cdk2 complexed with either cyclin E or cyclin D1, and given the many functions of PSF, it could have important implications on cellular activity.

Citing Articles

LncRNA SNHG12 promotes cell proliferation and inhibits apoptosis of granulosa cells in polycystic ovarian syndrome by sponging miR-129 and miR-125b.

Xuan F, Jin R, Zhou W, Ye Y, Ren Y, Lu J J Ovarian Res. 2024; 17(1):72.

PMID: 38566229 PMC: 10986130. DOI: 10.1186/s13048-024-01392-6.

Regulation of Cyclin D1 Degradation by Ubiquitin-Specific Protease 27X Is Critical for Cancer Cell Proliferation and Tumor Growth.

Alam S, Zunic A, Venkat S, Feigin M, Atanassov B Mol Cancer Res. 2022; 20(12):1751-1762.

PMID: 36001804 PMC: 9722596. DOI: 10.1158/1541-7786.MCR-22-0259.

The AMBRA1 E3 ligase adaptor regulates the stability of cyclin D.

Chaikovsky A, Li C, Jeng E, Loebell S, Lee M, Murray C Nature. 2021; 592(7856):794-798.

PMID: 33854239 PMC: 8246597. DOI: 10.1038/s41586-021-03474-7.

Primary neurons can enter M-phase.

Walton C, Zhang W, Patino-Parrado I, Barrio-Alonso E, Garrido J, Frade J Sci Rep. 2019; 9(1):4594.

PMID: 30872646 PMC: 6418114. DOI: 10.1038/s41598-019-40462-4.

Role of p27 as a transcriptional regulator.

Bachs O, Gallastegui E, Orlando S, Bigas A, Morante-Redolat J, Serratosa J Oncotarget. 2018; 9(40):26259-26278.

PMID: 29899857 PMC: 5995243. DOI: 10.18632/oncotarget.25447.

References

Ou L, Ferreira A, Otieno S, Xiao L, Bashford D, Kriwacki R . Incomplete folding upon binding mediates Cdk4/cyclin D complex activation by tyrosine phosphorylation of inhibitor p27 protein. J Biol Chem. 2011; 286(34):30142-51. PMC: 3191053. DOI: 10.1074/jbc.M111.244095. View

Ray D, Terao Y, Christov K, Kaldis P, Kiyokawa H . Cdk2-null mice are resistant to ErbB-2-induced mammary tumorigenesis. Neoplasia. 2011; 13(5):439-44. PMC: 3084620. DOI: 10.1593/neo.101704. View

Higashi H, Suzuki-Takahashi I, Saitoh S, Segawa K, Taya Y, Okuyama A . Cyclin-dependent kinase-2 (Cdk2) forms an inactive complex with cyclin D1 since Cdk2 associated with cyclin D1 is not phosphorylated by Cdk7-cyclin-H. Eur J Biochem. 1996; 237(2):460-7. DOI: 10.1111/j.1432-1033.1996.0460k.x. View

Morisaki H, Ando A, Nagata Y, Smith J, Ikeda K, Nakanishi M . Complex mechanisms underlying impaired activation of Cdk4 and Cdk2 in replicative senescence: roles of p16, p21, and cyclin D1. Exp Cell Res. 1999; 253(2):503-10. DOI: 10.1006/excr.1999.4698. View

Nakanishi M, Robetorye R, Smith J . The C-terminal region of p21SDI1/WAF1/CIP1 is involved in proliferating cell nuclear antigen binding but does not appear to be required for growth inhibition. J Biol Chem. 1995; 270(29):17060-3. DOI: 10.1074/jbc.270.29.17060. View

Coletta R, Christensen K, Reichenberger K, Lamb J, Micomonaco D, Huang L . The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1. Proc Natl Acad Sci U S A. 2004; 101(17):6478-83. PMC: 404070. DOI: 10.1073/pnas.0401139101. View

Wang D, He F, Zhang L, Zhang F, Wang Q, Qian X . The role of p27(Kip1) phosphorylation at serine 10 in the migration of malignant glioma cells in vitro. Neoplasma. 2010; 58(1):65-73. View

Heyd F, Lynch K . Phosphorylation-dependent regulation of PSF by GSK3 controls CD45 alternative splicing. Mol Cell. 2010; 40(1):126-37. PMC: 2954053. DOI: 10.1016/j.molcel.2010.09.013. View

Gulbis J, Kelman Z, Hurwitz J, ODonnell M, Kuriyan J . Structure of the C-terminal region of p21(WAF1/CIP1) complexed with human PCNA. Cell. 1996; 87(2):297-306. DOI: 10.1016/s0092-8674(00)81347-1. View

10.

Patton J, Porro E, Galceran J, Tempst P, Nadal-Ginard B . Cloning and characterization of PSF, a novel pre-mRNA splicing factor. Genes Dev. 1993; 7(3):393-406. DOI: 10.1101/gad.7.3.393. View

11.

Shav-Tal Y, Cohen M, Lapter S, Dye B, Patton J, Vandekerckhove J . Nuclear relocalization of the pre-mRNA splicing factor PSF during apoptosis involves hyperphosphorylation, masking of antigenic epitopes, and changes in protein interactions. Mol Biol Cell. 2001; 12(8):2328-40. PMC: 58597. DOI: 10.1091/mbc.12.8.2328. View

12.

Short J, Dere R, Houston K, Cai S, Kim J, Bergeron J . AMPK-mediated phosphorylation of murine p27 at T197 promotes binding of 14-3-3 proteins and increases p27 stability. Mol Carcinog. 2010; 49(5):429-39. PMC: 3818129. DOI: 10.1002/mc.20613. View

13.

Law M, Forrester E, Chytil A, Corsino P, Green G, Davis B . Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes. Cancer Res. 2006; 66(2):1070-80. DOI: 10.1158/0008-5472.CAN-05-1672. View

14.

Harms C, Albrecht K, Harms U, Seidel K, Hauck L, Baldinger T . Phosphatidylinositol 3-Akt-kinase-dependent phosphorylation of p21(Waf1/Cip1) as a novel mechanism of neuroprotection by glucocorticoids. J Neurosci. 2007; 27(17):4562-71. PMC: 6672985. DOI: 10.1523/JNEUROSCI.5110-06.2007. View

15.

Serrano M, Hannon G, Beach D . A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993; 366(6456):704-7. DOI: 10.1038/366704a0. View

16.

Okuda T, Hirai H, Valentine V, Shurtleff S, Kidd V, Lahti J . Molecular cloning, expression pattern, and chromosomal localization of human CDKN2D/INK4d, an inhibitor of cyclin D-dependent kinases. Genomics. 1995; 29(3):623-30. DOI: 10.1006/geno.1995.9957. View

17.

Kaneko S, Rozenblatt-Rosen O, Meyerson M, Manley J . The multifunctional protein p54nrb/PSF recruits the exonuclease XRN2 to facilitate pre-mRNA 3' processing and transcription termination. Genes Dev. 2007; 21(14):1779-89. PMC: 1920172. DOI: 10.1101/gad.1565207. View

18.

Hong F, Larrea M, Doughty C, Kwiatkowski D, Squillace R, Slingerland J . mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol Cell. 2008; 30(6):701-11. DOI: 10.1016/j.molcel.2008.04.027. View

19.

Sweeney K, Swarbrick A, Sutherland R, Musgrove E . Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells. Oncogene. 1998; 16(22):2865-78. DOI: 10.1038/sj.onc.1201814. View

20.

Lindahl T, Landberg G, Ahlgren J, Nordgren H, Norberg T, Klaar S . Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer. Carcinogenesis. 2003; 25(3):375-80. DOI: 10.1093/carcin/bgh019. View